Huntington Beach, CA – According to filings with the U.S. Securities and Exchange Commission, CoLabs is raising $16,500,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Laura Cohen played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About CoLabs
CoLabs Intl. Corp, established in 2008, is a global leader in the controlled delivery of topical cosmetics and drugs. It is a mid-stage biotechnology company, Nevada C corporation, with an administrative office in Huntington Beach, CA. CoLabs technology places drugs into micro-sized encapsulates, that have an electrostatic charge and suspend them in unique formulations. This highly advanced technology limits unwanted absorption of drugs and cosmetics into the skin which enter the body Importance of CoLabs. CoLabs new and globally unique delivery system significantly decreases absorption of potentially dangerous chemicals into the body and organ systems thereby avoiding potential toxic side-effects. For knowledgeable consumers, CoLabs products provide elegant skin delivery and enhanced consumer safety for topically applied drugs and cosmetics. Colabs mission is to develop our Innovative Technology, and Unique absorption limiting Science, into formulations that advance global health, science and the environment.

To learn more about CoLabs, visit http://www.colabsintl.com/

Contact:
Laura Cohen, President and Chief Executive Officer
888-878-5536

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved